MX2019008601A - Un derivado de oxazina base libre en forma cristalina. - Google Patents
Un derivado de oxazina base libre en forma cristalina.Info
- Publication number
- MX2019008601A MX2019008601A MX2019008601A MX2019008601A MX2019008601A MX 2019008601 A MX2019008601 A MX 2019008601A MX 2019008601 A MX2019008601 A MX 2019008601A MX 2019008601 A MX2019008601 A MX 2019008601A MX 2019008601 A MX2019008601 A MX 2019008601A
- Authority
- MX
- Mexico
- Prior art keywords
- crystalline form
- compound
- free base
- oxazine derivative
- pharmaceutical composition
- Prior art date
Links
- 239000012458 free base Substances 0.000 title 1
- 150000004893 oxazines Chemical class 0.000 title 1
- 229940125904 compound 1 Drugs 0.000 abstract 3
- 239000007787 solid Substances 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 abstract 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La invención se refiere a una forma sólida, a decir, la Forma A cristalina, del Compuesto 1, (ver Fórmula) (1), y divulga el proceso para la preparación de dicha forma sólida de Compuesto 1. Además se divulgan otras formas sólidas del Compuesto 1, que incluyen su forma de hidrato y amorfa. La presente invención además se refiere a una composición farmacéutica que comprende la Forma A cristalina de Compuesto 1, y métodos de uso de dicha forma y composición farmacéutica en el tratamiento o la prevención de la enfermedad de Alzheimer o angiopatía amiloide cerebral.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17152481 | 2017-01-20 | ||
| PCT/IB2018/050314 WO2018134761A1 (en) | 2017-01-20 | 2018-01-18 | A free base oxazine derivative in crystalline form |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019008601A true MX2019008601A (es) | 2019-09-10 |
Family
ID=57890668
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019008603A MX2019008603A (es) | 2017-01-20 | 2018-01-18 | Una composicion farmaceutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevencion de la enfermedad de alzheimer. |
| MX2019008601A MX2019008601A (es) | 2017-01-20 | 2018-01-18 | Un derivado de oxazina base libre en forma cristalina. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019008603A MX2019008603A (es) | 2017-01-20 | 2018-01-18 | Una composicion farmaceutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevencion de la enfermedad de alzheimer. |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20200048237A1 (es) |
| EP (2) | EP3570820A1 (es) |
| JP (2) | JP2020505363A (es) |
| KR (1) | KR20190126291A (es) |
| CN (1) | CN110167535A (es) |
| AR (1) | AR110758A1 (es) |
| AU (3) | AU2018209442A1 (es) |
| BR (2) | BR112019014825A2 (es) |
| CA (2) | CA3046304A1 (es) |
| CL (1) | CL2019002020A1 (es) |
| CO (2) | CO2019007670A2 (es) |
| CR (1) | CR20190333A (es) |
| IL (2) | IL267640A (es) |
| JO (2) | JOP20190178A1 (es) |
| MX (2) | MX2019008603A (es) |
| PE (2) | PE20191250A1 (es) |
| RU (1) | RU2019126022A (es) |
| SG (2) | SG11201905528XA (es) |
| TW (1) | TW201828943A (es) |
| UY (1) | UY37572A (es) |
| WO (2) | WO2018134760A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019142111A1 (en) * | 2018-01-18 | 2019-07-25 | Novartis Ag | Salt forms of an oxazine derivative bace inhibitor |
| CN112661667B (zh) * | 2020-12-28 | 2023-02-03 | 浦拉司科技（上海）有限责任公司 | 一种三氟乙脒的制备方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106117193B (zh) | 2011-01-13 | 2019-09-13 | 诺华股份有限公司 | 新的杂环衍生物及其在神经性疾病治疗中的应用 |
-
2017
- 2017-06-16 JO JOP/2019/0178A patent/JOP20190178A1/ar unknown
- 2017-06-16 JO JOP/2019/0180A patent/JOP20190180A1/ar unknown
-
2018
- 2018-01-18 BR BR112019014825-6A patent/BR112019014825A2/pt not_active Application Discontinuation
- 2018-01-18 TW TW107101806A patent/TW201828943A/zh unknown
- 2018-01-18 EP EP18701232.3A patent/EP3570820A1/en not_active Withdrawn
- 2018-01-18 CR CR20190333A patent/CR20190333A/es unknown
- 2018-01-18 EP EP18701600.1A patent/EP3571195A1/en not_active Withdrawn
- 2018-01-18 JP JP2019539215A patent/JP2020505363A/ja active Pending
- 2018-01-18 SG SG11201905528XA patent/SG11201905528XA/en unknown
- 2018-01-18 US US16/478,736 patent/US20200048237A1/en not_active Abandoned
- 2018-01-18 CN CN201880006121.3A patent/CN110167535A/zh active Pending
- 2018-01-18 BR BR112019014234-7A patent/BR112019014234A2/pt not_active IP Right Cessation
- 2018-01-18 US US16/478,704 patent/US20190388428A1/en not_active Abandoned
- 2018-01-18 SG SG11201905116PA patent/SG11201905116PA/en unknown
- 2018-01-18 WO PCT/IB2018/050312 patent/WO2018134760A1/en not_active Ceased
- 2018-01-18 MX MX2019008603A patent/MX2019008603A/es unknown
- 2018-01-18 CA CA3046304A patent/CA3046304A1/en not_active Abandoned
- 2018-01-18 WO PCT/IB2018/050314 patent/WO2018134761A1/en not_active Ceased
- 2018-01-18 AU AU2018209442A patent/AU2018209442A1/en not_active Abandoned
- 2018-01-18 JP JP2019539254A patent/JP2020505367A/ja active Pending
- 2018-01-18 MX MX2019008601A patent/MX2019008601A/es unknown
- 2018-01-18 AU AU2018208870A patent/AU2018208870A1/en not_active Abandoned
- 2018-01-18 PE PE2019001437A patent/PE20191250A1/es unknown
- 2018-01-18 PE PE2019001432A patent/PE20191346A1/es unknown
- 2018-01-18 CA CA3048346A patent/CA3048346A1/en not_active Abandoned
- 2018-01-18 KR KR1020197020514A patent/KR20190126291A/ko not_active Ceased
- 2018-01-18 RU RU2019126022A patent/RU2019126022A/ru not_active Application Discontinuation
- 2018-01-19 AR ARP180100124A patent/AR110758A1/es unknown
- 2018-01-19 UY UY0001037572A patent/UY37572A/es not_active Application Discontinuation
-
2019
- 2019-06-25 IL IL267640A patent/IL267640A/en unknown
- 2019-07-17 CO CONC2019/0007670A patent/CO2019007670A2/es unknown
- 2019-07-17 IL IL268131A patent/IL268131A/en unknown
- 2019-07-17 CO CONC2019/0007671A patent/CO2019007671A2/es unknown
- 2019-07-18 CL CL2019002020A patent/CL2019002020A1/es unknown
-
2020
- 2020-12-15 AU AU2020289738A patent/AU2020289738A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022003907A (es) | Compuestos y composiciones y usos de los mismos. | |
| MY178156A (en) | Compounds and their use as bace inhibitors | |
| WO2007058602A3 (en) | Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, alzheimer’s disease, neurodegeneration and dementia. | |
| MX2015012435A (es) | Derivados de 3-fenilpropilamina sustituidos para el tratamiento de enfermedades y trastornos oftalmicos. | |
| WO2017053868A8 (en) | C4-modified oleanolic acid derivatives for inhibition of il-17 and other uses | |
| EA201791802A1 (ru) | СШИТЫЕ ДИГИДРО-4H-ПИРАЗОЛО[5,1-c][1,4]ОКСАЗИНИЛОВЫЕ СОЕДИНЕНИЯ И АНАЛОГИ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ЦНС | |
| WO2017033208A3 (en) | Implantable naltrexone tablets | |
| WO2016199076A3 (en) | Polymorphic forms of afatinib free base and afatinib dimaleate | |
| PH12019500198A1 (en) | Compounds and compositions and uses thereof | |
| EP3248603A4 (en) | Pharmaceutical composition for prevention, treatment or delay of alzheimer's disease or dementia containing g protein-coupled receptor 19 agent as active ingredient | |
| MX2019008601A (es) | Un derivado de oxazina base libre en forma cristalina. | |
| MX2016008968A (es) | Compuestos organicos. | |
| PH12015501402A1 (en) | 4-hydroxy-2-methyl-5-(propan-2-ylidene)cyclohex-3-enecarbaldehyde for the prevention and treatment of a cognitive, neurodegenerative or neuronal disease | |
| WO2017214423A3 (en) | Derivatives of thailanstatin a, methods of treatment and methods of synthesis thereof | |
| ZA202103209B (en) | Monohydrate potassium salt of a thienopyridone derivative and its preparation process | |
| WO2014141169A3 (en) | Novel anti-neurodegenerative natural compounds isolated from alpiniae oxyphyllae fructus and total synthesis theirof | |
| TN2017000448A1 (en) | Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer's disease | |
| EP3634979A4 (en) | COMPOSITIONS AND METHODS OF TREATING ALZHEIMER'S MORBUS | |
| IL265656A (en) | Preparations and methods for the treatment of Alzheimer's disease and Parkinson's disease | |
| EP3085691A4 (en) | Method for preparing the anhydrous crystalline form of isoniazid-derived hydrazone, thus produced crystalline polymorph of the anhydrous form, use thereof for the treatment of alzheimer's disease, parkinsonism and other neurodegenerative disorders, and pharmaceutical composition | |
| EP3601570A4 (en) | METHOD FOR TREATMENT OF ALZHEIMER'S MORBUS | |
| WO2015186144A3 (en) | Method of inhibition of beta-secretase by using bis-o-demethylcurcumin for the prevention, management and treatment of neurodegenerative diseases | |
| MX2019002629A (es) | Formas cristalinas de compuestos terapéuticos y usos de los mismos. | |
| NZ727251A (en) | Novel polymorphic form of n-[2-(6-fluoro-1h-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine hydrochloride for the treatment of alzheimer’s | |
| PH12019502792A1 (en) | Tetrahydropyridopyrazine modulators of gpr6 |